Patents by Inventor Thomas G. Graeber

Thomas G. Graeber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220244263
    Abstract: The current disclosure provides for methods of identifying and treating small cell neuroendocrine (SCN) tumors and small-round-blue cell tumor (SRBCT). Aspects of the disclosure relate to a method comprising measuring the level of expression of one or more biomarkers from Tables 1-3 in a biological sample from a cancer patient. Further aspects relate to a method for treating small cell neuroendocrine (SCN) cancer or small-round-blue cell tumor (SRBCT) in a patient comprising administering a cancer treatment to the patient, wherein the cancer treatment is a treatment selected from Table 4A, 4B, or combinations of treatments from Table 4A and/or 4B.
    Type: Application
    Filed: May 28, 2020
    Publication date: August 4, 2022
    Applicant: The Regents of the University of California
    Inventors: Thomas G. GRAEBER, Nikolas G. BALANIS, Katherine M. SHEU, Owen N. WITTE, Favour ESEDEBE, Jung Wook PARK
  • Publication number: 20200163966
    Abstract: The current methods and compositions provide for a novel therapeutic method for treating patients diagnosed with melanoma, especially those that have become resistant to certain other therapies. Accordingly, certain aspects of the disclosure relate to a method for treating melanoma in a subject, the method comprising administering a composition comprising a ferroptosis-inducing agent or other dedifferentiated melanoma-targeting agent to the subject.
    Type: Application
    Filed: June 27, 2018
    Publication date: May 28, 2020
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas G. GRAEBER, Jennifer TSOI, Antoni RIBAS, Lidia ROBERT, Nicolaos PALASKAS
  • Patent number: 9448178
    Abstract: An immunocapture-based in vitro kinase assay on an integrated polydimethylsiloxane (PDMS) microfluidics platform that can reproducibly measure kinase activity from as few as 3,000 cells is described. For this platform, the standard radiometric 32P-ATP labeled phosphate transfer assay was adopted. Implementation on a microfluidic device required the development of methods for repeated trapping and mixing of solid-phase affinity micro beads. A solid state beta-particle camera imbedded directly below the microfluidic device was used to provide real-time quantitative detection of the signal from this and other microfluidic radio bioassays. The integrated device can measure ABL protein kinase activity from BCR-ABL positive leukemia patient samples, and can measure the small molecule phosphorylation such as phosphorylation of the deoxycytidine analog 18F-FAC by deoxycytidine kinase (dCK) isolated from cell lysates.
    Type: Grant
    Filed: March 2, 2013
    Date of Patent: September 20, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas G. Graeber, Hsian-Rong Tseng, Arion F. Hadjioannou (Chatziioannou), Cong Fang, Yanju Wang, Nam T. Vu